Halozyme Therapeutics Inc. (HALO) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Halozyme Therapeutics Inc. (HALO:NASDAQ), powered by AI.

Current Price
$69.64
P/E Ratio
26.3
Market Cap
8.3B
Sector
Healthcare
What is the Halozyme Therapeutics Inc. stock price forecast?

Halozyme Therapeutics Inc. is currently trading at $69.64. View real-time AI analysis on Alpha Lenz.

What is Halozyme Therapeutics Inc. insider trading activity?

View the latest insider trading data for Halozyme Therapeutics Inc. on Alpha Lenz.

What is Halozyme Therapeutics Inc.'s P/E ratio?

Halozyme Therapeutics Inc.'s P/E ratio is 26.3.

Halozyme Therapeutics Inc.

NASDAQ · HALO
$69.64-1.64(-2.30%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Halozyme Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Halozyme Therapeutics Inc. trades at a P/E of 26.3 (premium valuation) with strong ROE of 153.6%. 3Y revenue CAGR of 28.4% highlights clear growth momentum.

Ask for details

Company Overview

Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.

CEODr. Helen I. Torley M.B. Ch. B., M.R.C.P.
SectorHealthcare
IndustryBiotechnology
Employees350

Company Statistics

FY 2025

Profile

$8.35BMarket Cap
$1.40BRevenue
0.00Shares Out
350Employees

Margins

N/AGross
63.77%EBITDA
57.47%Operating
33.43%Pre-Tax
22.69%Net

Valuation

26.34P/E
170.97P/B
5.98EV/Sales
11.63EV/EBITDA
23.39P/FCF

Growth (CAGR)

28.38%Rev 3Yr
39.16%Rev 5Yr
44.23%Op Inc 3Yr
40.95%Op Inc 5Yr
16.17%Net Inc 3Yr
19.68%Net Inc 5Yr

Returns

13.81%ROA
153.59%ROE
21.14%ROIC

Financial Health

$133.82MCash & Cash Equivalents
$2.34BNet Debt
5073.36%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Halozyme Therapeutics Inc. (ticker: HALO) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 350 employees. Market cap is $8.3B.

The current price is $69.64 with a P/E ratio of 26.34x and P/B of 170.97x.

ROE is 153.59% and operating margin is 57.47%. Annual revenue is $1.4B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Halozyme Therapeutics Inc. (HALO) Stock Forecast 2026 $69.64 — Price, Financials & Analyst Targets | Alpha Lenz